13.11.2017 - 14.11.2017Hyatt Regency Boston, One Avenue de Lafayette, 02111 Boston, USA
Time: 8:20 am to 3:45 pm.
Kongressthemen This Anti-Fibrotic Drug Development conference will be a unique opportunity for drug developers focused on organ-specific indications to participate in a cross-disciplinary, multi-organ discussions in order to gain new insights into their anti-fibrotic drug development research.
Attending this comprehensive forum will enable you to; identify which fibrotic mechanisms are driving pathology changes in humans; effectively translate from preclinical to clinical development.
Kongressorganizer (PCO) Hanson Wade
Anmerkungen Speakers: Ray Jupp (UCB), Richard Marshall (GSK), Lisa Hazelwood (AbbVie), Peter Blume-Jensen (Xtuit Pharmaceuticals), Alexey Lugovskoy (Morphic Therapeutics), Seth Porter (FibroGen)
Kongressgebühr USD 2.699,00 (Register by August 18 to save $300: USD 2399,
Register by September 8 to save $200: USD 2499,
Register by October 6 to save $100: USD 2599,
Standard Rate: USD 2699.)
Veranstalter Kontakt 83 Great Titchfield Street W1W 6RH London Großbritannien